Young Faces of ALS Campaign to Surpass Half-Way Point with Three Appearances this Week
08/25/2010
ALS TDI Rated Highest Among All US-Based ALS Organizations by Charity Navigator
07/08/2010
"We are proud to announce your organization has earned our 4-star rating for its ability to efficiently manage and grow its finances. Approximately a quarter of the charities we evaluate have received our highest rating, indicating that ALS Therapy Development Institute executes its mission in a fiscally responsible way, and outperforms most other charities in America. This ’exceptional’ designation from Charity Navigator differentiates ALS Therapy Development Institute from its peers and demons
Young ALS Patients Come Together to End ALS with New National Campaign
05/21/2010
The ALS Therapy Development Institute (ALS TDI) announced today that it is supporting a new awareness campaign driven by several ALS patients diagnosed with the progressive neurodegenerative disease commonly known as Lou Gehrig’s disease before the age of 30. This campaign, called “Young Faces of ALS”, is designed and led by a group of seven young men and women and will consist of a group effort to visit each of the 30 Major League Baseball (MLB) parks during the 2010 baseball season. The Youn
ALS Research and Trials: Update from Washington
05/18/2010
This May 9th-11th, the ALS Association (ALSA) held its national advocacy conference in Washington, DC. The three-day event featured private chapter activities, breakout sessions and a full-day for advocates to visit “the Hill” to ask their congressional representatives to support additional funding for the ALS Registry and an ALS peer-review program within the Department of Defense. There were several hundred people that attended portions of the multi-day event, including several PALS and CALS
ALS TDI Takes the Stage at BIO in Chicago, Meets with Patients and Pharma
05/13/2010
“This is very personal to me. I have two cousins fighting ALS today, and my family constantly wonders and worries who it will affect next and when. I believe the attention that BIO and the CEOs have shown to our cause could be vital to ALS TDI’s success. This type of support gives me hope that one day my family and all those living with Lou Gehrig’s will no longer carry the burden of this debilitating illness. A cure, or even the ability to slow the progression of the disease, would bring re
Nature Genetics Article Shows a Link Between Gene Expression Profiling and Identification of Potential Treatment for ALS
03/28/2010
A biological treatment targeting the protein CD40L has a therapeutic effect on mice with amyotrophic lateral sclerosis (ALS), reports a new study published in Nature Genetics. The study suggests that ALS progression may be amenable to treatments that target the immune response.
Aestus Therapeutics, Inc. and ALS TDI Collaborate to Investigate Potential Treatments for ALS
03/17/2010
“Aestus is honored to be working with ALS TDI, an organization with a long history and excellent scientific reputation within the field of ALS research,” said Tage Honore, Ph.D., DSc., CEO & co-founder of Aestus. “By bringing together the Aestus technology for accelerated identification of potential drugs, and ALS TDI’s vast knowledge and experience with ALS disease models and clinical drug development, we look forward to the rapid and efficient discovery of novel, effective therapies against
International Group of Researchers Dedicate Guidelines for Preclinical Animal Research in ALS/MND to Sean F. Scott
03/08/2010
Albert Ludolf of the Department of Neurology at the University of Ulm in Germany headed up the group, which consisted of more than a dozen researchers from nine different countries spanning two continents.
Founder and board member, Jamie Heywood, talks about ALS research at TEDMED
02/03/2010
When Jamie Heywood's brother was diagnosed with ALS, he devoted his life to fighting the disease as well. The Heywood brothers built an ingenious website where people share and track data on their illnesses -- and they discovered that the collective data had enormous power to comfort, explain and predict.
California Stem Cell and ALS TDI Extend Collaboration
02/02/2010
Collaboration will further evaluate novel stem cell-derived product for the treatment of fatal neurodegenerative disease by regulating genes relevant to disease progression
December 10 Research Update Video Available Now
12/17/2008
All told, there were more than 120 people, mostly ALS patients and their family members, on the live webcast and conference call.
Driving4Life Campaign reaches $7.5 Million Milestone!
12/08/2008
Report from the 16th Annual Meeting of the International Alliance
12/04/2008
Each year, the ALS/MND Alliance hosts an international symposium emphasizing emerging topics from the clinical and research fields with relevance for ALS. As has been our custom, ALS TDI sent a team of researchers to Birmingham, UK, to meet with our international colleagues, participate in the discussions and presentations and report on our progress towards therapeutic development in ALS. This short report will highlight some of the noteworthy progress that has been made in the last year.
Prize4Life Selects ALS TDI Mouse Study Standards for its $1M Treatment Prize
11/05/2008
Last month, ALS TDI was named as one of the validation centers for Prize4Life, the non-profit ALS organization that announced its $1 million ALS/MND Treatment Prize on October 21, 2008. The Avi Kremer ALS Treatment prize, named at the request of an anonymous donor for Prize4Life's founder is a rolling prize that will be awarded to the first submission that meets the specified prize criteria. If no winning submissions are received the prize will be closed on October 15, 2010.
RGK Foundation provides ALS TDI with $1Million Grant
10/28/2008
RGK Foundation grant will support the creation of potential gene therapies to treat ALS
4th Annual Leadership Summit attracts 100+ people to Boston and 160+ to Webcast. Video Available Online Now.
10/20/2008
The ALS Therapy Development Institute (ALS TDI) announced the line-up for its upcoming, annual ALS research symposium, part of the fourth annual ALS TDI Leadership Summit. The symposium will take place this October 20th at the Beacon Hill Holiday Inn in Boston, Mass.
ALS TDI to Present at the International Meeting in Birmingham, UK
10/10/2008
ALS TDI will send a team of researchers to the International meeting held Nov 3-5 not only to keep abreast of the latest developments in pre-clinical and clinical research on ALS but also to share our results working with the ALS mouse model.
ALS Patients and Researchers Unite in Boston for 4th Annual Leadership Summit
10/09/2008
Afternoon Session of Research Symposium to be Webcast
10/09/2008
ALS TDI and Clinics Partner to Accelerate Identification of Biomarkers
08/19/2008
ALS Therapy Development Institute (ALS TDI) announces the acceleration of an ALS biomarker effort using blood samples collected through an expanded network of clinical partnerships. These ongoing projects are part of the Institute's extensive effort to identify the altered expression of genes and proteins, at the onset of, and throughout the progression of the fatal neurodegenerative disease known as amyotrophic lateral sclerosis (ALS, commonly known as Lou Gehrig's disease).